Home Cart Sign in  
Chemical Structure| 409345-29-5 Chemical Structure| 409345-29-5

Structure of JNJ16259685
CAS No.: 409345-29-5

Chemical Structure| 409345-29-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

JNJ16259685 is a selective antagonist at the mGlu1 receptors, and inhibits the synaptic activation of mGlu1 in a concentration-dependent manner with IC50 of 19 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of JNJ16259685

CAS No. :409345-29-5
Formula : C20H23NO3
M.W : 325.40
SMILES Code : O=C(C1=CC=C2N=C3C(CCCO3)=CC2=C1)[C@H]4CC[C@@H](OC)CC4
MDL No. :MFCD08690525

Safety of JNJ16259685

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of JNJ16259685

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Purkinje cells 19 nM 10 minutes To evaluate the inhibitory effect of JNJ16259685 on mGlu1 receptor-mediated EPSP in Purkinje cells, showing that JNJ16259685 inhibits synaptic activation of mGlu1 in a concentration-dependent manner. Br J Pharmacol. 2007 Jul;151(6):870-6
Rat VTA dopamine neurons 100 nM 10 minutes JNJ16259685 blocked DHPG-induced depression of IPSCs, indicating the role of mGluR1 in inhibitory synaptic transmission in VTA dopamine neurons. Neuropsychopharmacology. 2013 Jun;38(7):1308-21
cerebellar nuclear neurons 0.2 μM 10–15 min To test the effect of mGluR1 antagonist JNJ16259685 on the firing rate of cerebellar nuclear neurons, results showed a significant reduction in the firing rate increase when combined with MPEP J Neurosci. 2011 Jul 13;31(28):10283-92

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice C57BL/6J mice and Homer2 knockout mice Bilateral infusion into the shell subregion of the nucleus accumbens (NAC) 0–30 pg/side Single injection, alcohol intake assessed over 2 hours JNJ-16259685 dose-dependently reduced alcohol consumption in C57BL/6J mice, but this effect was absent in Homer2 KO mice. Neuropharmacology. 2014 Apr;79:679-87
Mice Eif4ebp2 knock-out mice Intraperitoneal injection 0.3 mg/kg Single dose, tested 30 min later JNJ16259685 reversed the deficits in social interaction and repetitive behaviors (marble burying) in Eif4ebp2 knock-out mice. J Neurosci. 2015 Aug 5;35(31):11125-32
Rats Chronic constrictive injury (CCI) model of sciatic nerve Intraperitoneal injection 5 mg/kg Once daily for 3 or 7 days JNJ16259685 prevented thermal hyperalgesia at both 3 and 7 days post-CCI but not mechanical allodynia. Additionally, JNJ16259685 increased the expression of the anti-apoptotic gene bcl-2 and inhibited the over-expression of APAF-1 and caspase-7 genes. Pharmacol Res. 2008 Mar;57(3):223-33
Nude mice Melanoma cell xenograft model Subcutaneous injection 10mg/kg Five times per week for 22 days JNJ16259685 significantly decreased the rate of SK2 and SK5 melanoma tumor growth Oncogene. 2015 May 21;34(21):2711-20
Male Sprague-Dawley rats Cocaine-induced conditioned place preference (CPP) model Bilateral intra-VTA microinjection 0.1 ng/side Injected 30 min prior to each cocaine or saline pairing, for 8 days JNJ16259685 significantly attenuated cocaine-induced CPP, suggesting that mGluR1-dependent protein synthesis is critically involved in the acquisition of cocaine CPP. Neuropsychopharmacology. 2013 Jun;38(7):1308-21
Rat Cerebellar slice model Systemic administration IC50 value of 19 nM Tested the antagonistic effect of JNJ16259685 on synaptic transmission in cerebellar Purkinje neurons, showing high selectivity and potency. Br J Pharmacol. 2007 Jul;151(6):723-4
Rats Conditioned place preference model Intraperitoneal injection 0.3mg/kg Once daily for two days To evaluate the effect of JNJ16259685 on the maintenance of methamphetamine-induced conditioned place preference, results showed that JNJ16259685 did not influence the maintenance of methamphetamine-induced CPP. Eur Neuropsychopharmacol. 2013 Jul;23(7):691-6
Mice SCA1 82Q mouse model Subcutaneous injection 0.03 mg/kg Single dose JNJ16259685 shortened the prolonged mGluR1 currents and improved moderate ataxia J Neurosci. 2016 May 4;36(18):4910-6
Rats Alcohol discrimination training model Intraperitoneal injection 0.3–3 mg/kg Single administration To evaluate the effect of mGlu1 receptor antagonism on the discriminative stimulus effects of alcohol, results showed that JNJ16259685 did not alter the discriminative stimulus effects of alcohol. J Neurosci. 2009 Jul 29;29(30):9582-91
Mouse Cerebellar slices Perfusion 0.2 μM Single administration, recordings made 10–15 min after perfusion To test the effect of JNJ16259685 on the firing rate of cerebellar nuclear neurons, results showed a significant reduction in the firing rate increase when combined with MPEP J Neurosci. 2011 Jul 13;31(28):10283-92

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.07mL

0.61mL

0.31mL

15.37mL

3.07mL

1.54mL

30.73mL

6.15mL

3.07mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories